INFINITY GAMMAXL

K033600 · Draeger Medical Systems, Inc. · MHX · Dec 11, 2003 · Cardiovascular

Device Facts

Record IDK033600
Device NameINFINITY GAMMAXL
ApplicantDraeger Medical Systems, Inc.
Product CodeMHX · Cardiovascular
Decision DateDec 11, 2003
DecisionSESE
Submission TypeSpecial
Regulation21 CFR 870.1025
Device ClassClass 2
AttributesPediatric

Intended Use

The intended use of this device is to monitor heart rate, respiration rate, invasive pressure, noninvasive pressure, arrhythmia, temperature, arterial oxygen saturation and pulse rate, central apnea, end-tidal carbon dioxide, and ST Segment Analysis. This device will produce visual and audible alarms if any of these parameters vary beyond preset limits and produce timed or alarm recordings. This device will connect to R50 recorders, either directly or via the INFINITY network.

Device Story

INFINITY GammaXL is a physiological patient monitor; inputs include ECG, invasive/non-invasive pressure, temperature, SpO2, respiration, and end-tidal CO2 sensors. Device processes signals to provide real-time vital sign data, arrhythmia detection, and ST segment analysis; outputs include visual/audible alarms and timed/alarm recordings. Used in clinical environments by trained healthcare professionals (physicians, nurses, technicians) to assess patient status. Device connects to R50 recorders directly or via INFINITY network. Modifications in VF4 release include updated branding, menu structure, and a new top-center alarm indicator (red/yellow). Device aids clinical decision-making by alerting staff to parameter deviations; not MRI compatible.

Clinical Evidence

No clinical data provided. Substantial equivalence is supported by internal design control testing and bench testing of the modified alarm indicator.

Technological Characteristics

Physiological monitor with integrated arrhythmia and ST segment analysis. Features a physical form factor with a top-center visual alarm indicator. Connectivity via INFINITY network to R50 recorders. Software-based processing for vital sign monitoring and alarm generation. Not MRI compatible.

Indications for Use

Indicated for adult, pediatric, and neonatal patient populations for monitoring of heart rate, respiration, invasive/non-invasive pressure, temperature, SpO2, pulse rate, central apnea, and end-tidal CO2. Arrhythmia and ST segment analysis are indicated for adult and pediatric populations only, excluding neonates.

Regulatory Classification

Identification

The arrhythmia detector and alarm device monitors an electrocardiogram and is designed to produce a visible or audible signal or alarm when atrial or ventricular arrhythmia, such as premature contraction or ventricular fibrillation, occurs.

Special Controls

*Classification.* Class II (special controls). The guidance document entitled “Class II Special Controls Guidance Document: Arrhythmia Detector and Alarm” will serve as the special control. See § 870.1 for the availability of this guidance document.

Predicate Devices

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ ## 510(k) SUMMARY as required per 807.92(c) Submitters Name, Address: Draeger Medical Systems, Inc. 16 Electronics Avenue Danvers, MA 01923 Tel: (978) 907-7500 Fax: (978) 750-6879 Official Correspondent: Connie Hertel, Director Quality Assurance & Regulatory Affairs Contact person for this submission: Penelope H. Greco Regulatory Submissions Manager Date submission was prepared: November 12, 2003 Trade Name, Common Name and Classification Name: INFINITY GammaXL Trade Name: Common Name, Classification Name, Class and Regulation Number: | Common Name | Product Code | Class | Regulation Number | |--------------------------------------------------------------------------|--------------|-------|-------------------| | Monitor, Physiological, Patient (with Arrhythmia<br>Detection or Alarms) | MHX | II | 870.1025 | | Arrhythmia Detector & Alarm | 74DSI | II | 870.1025 | | System, Network and Communication,<br>Physiological Monitors | MSX | II | 870.2300 | Legally Marketed Device: INFINITY SC 6802XL K030313 / K993974 ## Description of Device Modifications: The VF4 release of the INFINITY GammaXL (SC 6802XL) supports the "look and feel" of the Draeger Medical product line, including the Draeger logo, colors, menu structure, and physical form. An alarm indicator has been added to the top center of the device that illuminates in red or yellow for the purpose of displaying both life threatening and serious alarms respectively. Testing in accordance with internal design control procedures has verified that the INFINITY GammaXL with VF4 modifications is as safe and effective as the SC 6802XL as submitted in 510(k) K030313. ## Intended Use: The intended use of this device is to monitor heart rate, respiration rate, invasive pressure, noninvasive pressure, arrhythmia, temperature, arterial oxygen saturation and pulse rate, central apnea, end-tidal carbon dioxide, and ST Segment Analysis. This device will produce visual and audible alarms if any of these parameters vary beyond preset limits and produce timed or alarm recordings. This device will connect to R50 recorders, either directly or via the INFINITY network. Assessment of non-clinical performance data for equivalence: Section J Assessment of clinical performance data for equivalence: Not applicable Biocompatability: Not applicable Sterilization: Not applicable Standards: Section J ## Draeger Medical Systems, Inc. 16 Electronics Avenue Danvers, MA 01923 Tel: (978) 907-7500 Fax: (978) 750-6879 {1}------------------------------------------------ Food and Drug Administration Public Health Service DEC 1.1 2003 9200 Corporate Boulevard Rockville MD 20850 Draeger Medical Systems, Inc. c/o Ms. Penelope H. Greco Regulatory Submissions Manager 16 Electronics Avenue Danvers, MA 01923 Re: K033600 Trade Name: INFINITY GammaXL Regulation Number: 21 CFR 870.1025 Regulation Name: Arrhythmia Detector and Alarm Regulatory Class: Class II (two) Product Code: MHX Dated: November 12, 2003 Received: November 14, 2003 Dear Ms. Greco: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to ecommerce provided in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). the Coometer Fee (110) inn the device, subject to the general controls provisions of the Act. The I ou may, aterest, mains of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it If your de rio is enation (controls. Existing major regulations affecting your device can may or defect to the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. {2}------------------------------------------------ Page 2 - Ms. Penelope H. Greco Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set Of R ratt 60779 to one (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) rms leter with as a minding of substantial equivalence of your device of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please If you acono eposition of Compliance at (301) 594-4646. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html Sincerely vours. Elsa D'Arz hr Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {3}------------------------------------------------ 510(k) Number (if known): ____________________________________________________________________________________________________________________________________________________ Device Name: INFINITY GammaXL Indications for Use: This device is capable of monitoring: - Heart Rate . - Respiration Rate . - Invasive Pressure . - Non-Invasive Pressure . - . Arrhythmia - Temperature ◆ - Arterial oxygen saturation . - Pulse rate . - (central) apnea . - end-tidal CO2 . - ST Segment Analysis . This device will produce visual and audible alarms if any of these parameters vary beyond preset limits and produce timed or alarm recordings. This device will connect to R50 recorders, either directly or via the INFINITY network. The device is intended to be used in the environment where patient care is provided by Healthcare Professionals, i.e. physicians, nurses, and technicians, trained on the use of the device, who will determine when use of the device is indicated, based upon their professional assessment of the patient's medical condition. The devices are intended for use in the Adult, Pediatric and Neonatal populations, with the exception of Arrhythmia and ST Segment Analysis which are not intended for the neonatal population. MRI Compatibility Statement: The INFINITY GammaXL is not compatible for use in a MRI magnetic field. (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) | Prescription Use (Per 21 CFR 801.109) | <div style="display:flex; align-items:center;">X</div> | OR | Over-The-Counter Use | |---------------------------------------|--------------------------------------------------------|----|----------------------| |---------------------------------------|--------------------------------------------------------|----|----------------------| (Optional Format 1-2-96) | Prescription Use (Per 21 CFR 801.109) | X | |---------------------------------------|--------------------------------------------------| | | QDA FRBPZ 12/11/93 | | 510(k) Number: | K033600 | | | Division of Cardiovascular & Respiratory Devices |
Innolitics

Panel 1

/
Sort by
Ready

Predicate graph will load when search results are available.

Embedding visualization will load when search results are available.

PDF viewer will load when search results are available.

Loading panels...

Select an item from the tree

Click any panel, subpart, regulation, product code, or device to see details here.

Section Matches

Results will appear here.

Product Code Matches

Results will appear here.

Special Control Matches

Results will appear here.

Loading collections...